Myeloid sarcoma
MONDO:0006861A tumor mass composed of myeloblasts or immature myeloid cells. It occurs in extramedullary sites or the bone. (WHO, 2001)
Also known as: chloroma, extramedullary myeloid tumor, extramedullary myeloid tumour, myeloid sarcoma, sarcoma, myeloid, malignant, MS, granulocytic sarcoma
3142 clinical trials for this condition and its sub-types, 27 tagged with Myeloid sarcoma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Myeloid sarcoma
-
Granulocytic sarcoma 0 trials
-
New drug combo aims to stop blood cancer relapse after transplant in kids
Disease control OngoingThis study tests whether giving two drugs, decitabine and filgrastim, after a stem cell transplant can help prevent blood cancers like AML and MDS from coming back in children and young adults. About 37 participants will receive the drug combination for up to 6 cycles. The main g…
Phase 2 • Sponsor: Franziska Wachter • Aim: Disease control
Last updated Aug 22, 2026 00:00 UTC
-
Childhood leukaemia trial seeks best chemo cocktail
Disease control OngoingThis trial investigates the best way to treat children with acute myeloid leukaemia (AML) by comparing different chemotherapy drugs and doses. It tests whether adding up to three doses of the targeted drug gemtuzumab ozogamicin to standard chemo is safe and effective. The study a…
Phase 3 • Sponsor: University of Birmingham • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New strategy aims to boost chemo power in childhood leukemia
Disease control OngoingThis phase II trial tests whether giving a short course of azacitidine or decitabine before standard chemotherapy can improve outcomes for children with newly diagnosed acute myeloid leukemia (AML). The study enrolls 206 participants and focuses on tolerability, changes in DNA me…
Phase 2 • Sponsor: St. Jude Children's Research Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Immune cell therapy aimed at autoimmune diseases hits early snag
Disease control CancelledThis early-phase trial planned to test a one-time infusion of genetically modified immune cells (CAR-T cells) targeting CD19 in people with several autoimmune diseases, including lupus and multiple sclerosis. The goal was to see if it was safe and could reduce harmful antibodies.…
Early phase 1 • Sponsor: Nanjing Bioheng Biotech Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
MS patients switch meds: will a cheaper option work just as well?
Disease control OngoingThis study looks at people with relapsing-remitting multiple sclerosis who switched from the drug MabThera to a similar, lower-cost medicine called Rixathon. Researchers want to see if the switch changes signs of nerve damage, new brain lesions, relapses, or disability. They will…
Sponsor: Uppsala University • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
New app aims to bridge depression care gap for MS patients
Symptom relief OngoingThis study tests a smartphone app called MS CATCH that lets people with multiple sclerosis regularly report their mood to their neurologist. The goal is to improve how doctors screen and treat depression in MS. About 100 adults with MS and mild-to-moderate depression are taking p…
Sponsor: University of California, San Francisco • Aim: Symptom relief
Last updated Sep 16, 2026 00:00 UTC
-
Brain scan breakthrough could spot MS cognitive decline early
Knowledge-focused By invitation onlyThis study is testing whether a new type of MRI can detect changes in the brain that lead to memory and thinking problems in people with multiple sclerosis (MS). Researchers will scan 75 adults with MS and give them thinking and memory tests. The goal is to see if the new MRI mea…
Sponsor: University of Wisconsin, Madison • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:25 UTC
-
New study observes patients getting nasal stem cell therapy for brain conditions
Knowledge-focused By invitation onlyThis observational study follows 36 people with neurologic conditions like traumatic brain injury, cerebral palsy, multiple sclerosis, or Alzheimer's who are already receiving intranasal MuSE stem cell or exosome therapy as part of their routine care. Researchers track safety and…
Sponsor: Healing Hope International • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:05 UTC